Click on a filter below to refine your search. Remove a filter to broaden your search.
Did you mean: eformes
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness